MedPath

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
Registration Number
NCT00003615
Lead Sponsor
Eastern Cooperative Oncology Group
Brief Summary

RATIONALE: Immunotoxins such as denileukin diftitox can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for non-Hodgkin's lymphoma.

PURPOSE: Phase II trial to study the effectiveness of denileukin diftitox in treating patients who have non-Hodgkin's lymphoma that has not responded to previous treatment.

Detailed Description

OBJECTIVES: I. Determine the objective response rate in patients with previously treated stage I, II, III, or IV low- or intermediate-grade B-cell non-Hodgkin's lymphoma treated with denileukin diftitox. II. Determine the time to progression, duration of remission, and time to treatment failure in patients after treatment with this therapy. III. Determine the toxicity of this therapy in these patients. IV. Correlate the results of the inteleukin-2 receptor assay with treatment outcomes in these patients.

OUTLINE: Patients are stratified according to interleukin-2 receptor classification (positive vs negative). Patients receive immunotoxin therapy with denileukin diftitox IV over 15-60 minutes on days 1-5. Treatment repeats every 21 days for 2-6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 33 patients will be accrued for the interleukin-2 (IL-2) receptor-positive stratum and a total of 11-44 patients will be accrued for the IL-2 receptor-negative stratum.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
77
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (10)

Robert H. Lurie Comprehensive Cancer Center, Northwestern University

🇺🇸

Chicago, Illinois, United States

CCOP - Geisinger Clinic and Medical Center

🇺🇸

Danville, Pennsylvania, United States

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

Morristown Memorial Hospital

🇺🇸

Morristown, New Jersey, United States

CCOP - Southern Nevada Cancer Research Foundation

🇺🇸

Las Vegas, Nevada, United States

Trinitas Hospital - Jersey Street Campus

🇺🇸

Elizabeth, New Jersey, United States

Overlook Hospital

🇺🇸

Summit, New Jersey, United States

Riverview Medical Center - Booker Cancer Center

🇺🇸

Red Bank, New Jersey, United States

Hackensack University Medical Center

🇺🇸

Hackensack, New Jersey, United States

Hunterdon Regional Cancer Center

🇺🇸

Flemington, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath